Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer

• DOI: 10.1016/j.esmoop.2022.100445
• Publication Date: 2022-04-07T22:35:27Z
• Authors: M. Stares; T.E. Ding; C. Stratton; F. Thomson; M. Baxter; H. Cagney; K. Cumming; A. Swan; F. Ross; C. Barrie; K. Maclennan; S. Campbell; T. Evans; A. Tufail; S. Harrow; H. Lord; B. Laird; M. MacKean; I. Phillips
• Keywords: Absolute neutrophil count; Progression-free survival

•Biomarkers of systemic inflammation are strong prognostic factors in patients with NSCLC.•The Scottish Inflammatory Prognostic Score is a simple score combining albumin and neutrophil count.•SIPS objectively stratifies survival clinically meaningful timeframe. IntroductionPembrolizumab an established first-line option for advanced non-small-cell lung cancer (NSCLC) expressing programmed death-ligand 1 ≥50%. Durable responses seen subset patients; however, many derive little clinical benefit. Biomarkers the inflammatory response predict NSCLC. We evaluated their significance receiving pembrolizumab NSCLC.MethodsPatients treated NSCLC expression ≥50% at two regional centres were identified. Pretreatment biomarkers (white cell count, neutrophil/lymphocyte ratio, platelet/lymphocyte albumin, nutritional index) recorded. The relationship between these progression-free (PFS) overall (OS) examined.ResultsData available 219 patients. On multivariate analysis, count independently associated PFS (P < 0.001, P = 0.002, respectively) OS (both 0.001). A was explored. (SIPS) assigned point each <35 g/l >7.5 × 109/l to give three-tier categorical score. SIPS predicted [hazard ratio 2.06, 95% confidence interval (CI) 1.68-2.52 0.001)] 2.33, CI 1.86-2.92 0.001)]. It stratified from 2.5 (SIPS2), 8.7 (SIPS1) 17.9 months (SIPS0) 0.001) 5.1 12.4 28.7 relative risk death before 6 2.96 (95% 1.98-4.42) SIPS2 compared those SIPS0-1 0.001).ConclusionsSIPS, predicts pembrolizumab. Unlike proposed scores, uses only routinely collected pretreatment test results provides across time periods that may assist clinicians treatment decisions. advocate validation utility this other immune checkpoint inhibitor settings.